Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

29. Februar 2016 02:26 ET | Quelle: CareDx, Inc.

CareDx Announces Revised Timeline to Its Offer to Acquire Allenex

BRISBANE, Calif., Feb. 29, 2016 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically...
09. Februar 2016 03:01 ET | Quelle: CareDx, Inc.

CareDx Announces Revised Agreement to Purchase 78 Percent of the Outstanding Shares of Allenex AB and Plans to Launch Tender for Remaining Shares in First Quarter 2016

BRISBANE, Calif., Feb. 09, 2016 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically...
02. Februar 2016 16:37 ET | Quelle: CareDx, Inc.

CareDx to Participate in Upcoming Healthcare Conferences in February 2016: Leerink, BIO CEO & BTIG

BRISBANE, Calif., Feb. 02, 2016 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically...
12. Januar 2016 16:05 ET | Quelle: CareDx, Inc.

CareDx and Diaxonhit Announce Completion of Technology Transfer of AlloMap® Test in Europe

BRISBANE, Calif. and PARIS, Jan. 12, 2016 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically...
23. Dezember 2015 20:28 ET | Quelle: CareDx, Inc.

UPDATE: CareDx Completes Analytical Validation of AlloSure: A Next-Generation Sequencing Test Measuring Donor-Derived Cell-Free DNA in Transplant Patients

BRISBANE, Calif., Dec. 23, 2015 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically...
23. Dezember 2015 08:00 ET | Quelle: CareDx, Inc.

CareDx Completes Analytical Validation of AlloSure: A Next-Generation Sequencing Test Measuring Donor-Derived Cell-Free DNA in Transplant Patients

BRISBANE, Calif., Dec. 23, 2015 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically...
16. Dezember 2015 05:02 ET | Quelle: CareDx, Inc.

CareDx Announces Agreement to Purchase 78 Percent of the Outstanding Shares of Allenex AB and Plans to Launch Tender for Remaining Shares in First Quarter 2016

BRISBANE, Calif., Dec. 16, 2015 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically...
17. November 2015 18:35 ET | Quelle: CareDx, Inc.

CMS Revises Its Pricing Determination for AlloMap(R)

Reimbursement for Heart Transplant Surveillance Testing to Remain At Previous Level Decision is Victory for Transplant Community BRISBANE, Calif., Nov. 17, 2015 (GLOBE NEWSWIRE) -- CareDx, Inc....
17. November 2015 16:05 ET | Quelle: CareDx, Inc.

CareDx to Participate in Upcoming Investor Conferences

BRISBANE, Calif., Nov. 17, 2015 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high...
11. November 2015 16:05 ET | Quelle: CareDx, Inc.

CareDx, Inc. Reports Third Quarter 2015 Financial Results

BRISBANE, Calif., Nov. 11, 2015 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high...

Vorherige Seite